certificate of analysis raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-02-16. Anything still debated is marked as such rather than presented as settled.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Published research on the intact protein is substantial, covering actin regulation, cell migration, and wound models. Research using the heptapeptide fragment specifically is far smaller, and much of the circulating material originates in supplier documentation rather than peer-reviewed reports. Where fragment studies do exist, they often employ different sequences, chain lengths, or terminal modifications, which complicates direct comparison across papers. Readers encountering claims about TB-500 should therefore separate evidence about thymosin beta-4 from evidence about the fragment itself.
Discussion of the compound frequently appears alongside other short peptides described as fragments of larger proteins. That grouping is convenient but can be misleading, because fragment length, charge, and modification state determine how a peptide behaves in solution and in any experimental system. A seven-residue acetylated peptide and a full-length protein differ in mass by roughly an order of magnitude, and they cannot be assumed to share distribution or binding properties. Precision about which molecule is under discussion is the single most useful step when reading such material.
TB-500 is a shorthand label used in supplier catalogs and online discussion for a short synthetic peptide described as a fragment of thymosin beta-4. Most product listings present it as the N-terminally acetylated heptapeptide Ac-LKKTETQ, a sequence corresponding to the actin-binding region of the parent protein. The name is not a formal chemical designation and does not appear in standard nomenclature systems. Because labeling practices vary between vendors, two products sold under the same name may not contain the same molecule, and the stated sequence should be treated as a claim rather than a fixed definition.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
The compound is most often distributed as a lyophilized powder, appearing white to off-white and forming a loose cake or fluffy solid. It is hygroscopic to some degree, so brief exposure to humid air can add water weight and complicate weighing. The peptide dissolves readily in water and in neutral aqueous buffers, and aqueous solubility is generally described as high, well above the concentrations used in typical assays. Some polar organic solvents are also usable, which matters when a concentrated stock is prepared before dilution into buffer.
Storage recommendations center on keeping the dry powder cold, dry, and dark. A freezer at -20 degrees Celsius or below is conventional, and desiccant is often included to limit moisture uptake. Once dissolved, the peptide is less stable, and solutions are typically kept frozen and thawed only once. Repeated freeze-thaw cycles are a common source of losses because they promote aggregation and adsorption to container surfaces. Working aliquots are therefore prepared in advance, and glass or low-binding plastic is usually preferred over ordinary laboratory plastic.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.
Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.
Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.
Once in solution, short peptides are generally less stable than the dry powder, and repeated freeze-thaw cycles are a common cause of loss. Laboratory guidance usually calls for aliquoting on first dissolution and storing aliquots at -20 °C or below, away from light. Adsorption to plastic and glass surfaces can lower measured concentration, particularly at low concentrations, so container material and buffer choice can affect results. Visible cloudiness, colour change or unexpected precipitate is a signal to re-check the material.
Purity is normally assessed by reversed-phase HPLC, with the main peak reported as a percentage of total peak area, while identity is confirmed by mass spectrometry. Electrospray and MALDI-TOF instruments are both used, and the observed mass is compared with the value calculated from the stated sequence. Ion-exchange or size-exclusion methods appear where aggregation or charge variants are of interest. Water content, counter-ion content and residual trifluoroacetate from purification are separate variables that can shift the measured mass and should be weighed when reading a certificate of analysis.
According to Garth, Kitchener's Army, in which Tolkien served, at once marked existing social boundaries and counteracted the class system by throwing everyone into a desperate situation together. Tolkien was grateful, writing that it had taught him "a deep sympathy and feeling for the Tommy; especially the plain soldier from the agricultural counties".
Many of the organisms, such as Charnia, found in Mistaken Point, were not like any organisms seen today. They had distinct bodies, however were lacking a head and digestive regions. Rather their body was organized in a very simple, fractal-like branching pattern. Every element of the body was finely branched and grew by repetitive branching. This allowed the organism to have a large surface area and maximize nutrient absorption without needing a mouth and digestive system. However, there was minimal genetic information and therefore did not have the requirements that would have allowed them to evolve more efficient feeding techniques. This means they were probably outcompeted by other organisms, and thus became extinct. The organisms found in the Ediacaran Hills in Southern Australia displayed either radially symmetric body plans or, one organism, Spriggina, displayed the first bilateral symmetry. The Ediacaran Hills are thought to have once had a shallow reef where more light could penetrate the bottom of the ocean floor. This allowed for more diversity of organisms. The organisms found here resemble relatives of the cnidarians, mollusks or annelids.
== Sunderland's classification == In 1951, Sunderland expanded Seddon's classification to five degrees. The first two are the same as Seddon's. With each degree, the severity of the injury increases and has larger structural disruption and poorer prognosis. Sunderland's third-degree and fourth-degree are included within Seddon's axonotmensis. Sunderland's third-degree is nerve fiber interruption. This includes an endoneurium lesion with disruption of the axon and endoneurium, but an intact epineurium and perineurium. Recovery from a third-degree injury may require surgical intervention due to misdirected regeneration that is caused by endoneurial damage. In fourth-degree injury, only the epineurium remain intact, and a complete block to axonal regeneration could occur, requiring surgical repair. Sunderland's fifth-degree is included within Seddon's neurotmesis. Fifth-degree lesion is a complete transection of the nerve, including the epineurium. Recovery requires appropriate surgical treatment since there is no spontaneous recovery expected.
Sources: en.wikipedia.org
== Clinical significance == The amount of expression of adiponectin has been observed to be related to diseases such as insulin resistance, obesity, and type 2 diabetes. Decreased amounts of the protein indicates that there is a higher probability of receiving said diseases. Because the GSTK1 is seen to play a role in the multimerization of adiponectin, this enzyme can regulate the concentration of adiponectin and thus enhance insulin sensitivity and protect against diabetes. Also, the GSTK1 gene is unregulated when it is inflicted with oxidative stress and are over expressed in many tumors leading to difficulties during cancer chemotherapy. Moreover, GSTK1 gene expression has been seen to increase significantly in correlation to drug resistance in tumor cells such as erythroleukemia and mammary adenocarcinoma suggesting that it, along with GSTP1 and GSTA4, could be responsible for the drug resistance. GSTK1 can also be a potential tool to help investigate cancer. Tyrosine phosphorylated proteins are responsible for many of the cell functions such as the cell’s growth, division, adhesion, and motility. These activities are also very related to cancer and thus studying this protein could allow access to information which could classify tumors for prognosis and prediction. Due to GSTK1’s C-terminal SH2 domain, tyrosine phosphorylated proteins can bind to it and allow for easier detection to which the protein can be studied.
By late June, senior counter-terrorism official Richard Clarke and CIA director George Tenet were "convinced that a major series of attacks was about to come", although the CIA believed the attacks would likely occur in Saudi Arabia or Israel. In early July, Clarke put domestic agencies on "full alert", telling them, "Something spectacular is going to happen here, and it's going to happen soon." He asked the FBI and the State Department to alert the embassies and police departments, and the Defense Department to go to "Threat Condition Delta." Clarke later wrote: Somewhere in CIA there was information that two known al-Qaeda terrorists had come into the United States. Somewhere in the FBI, there was information that strange things had been going on at flight schools in the United States. [...] They had specific information about individual terrorists from which one could have deduced what was about to happen. None of that information got to me or the White House.
== External links == Nobel Prize in Physics 1989 The High-precision Penning Trap Mass Spectrometer SMILETRAP in Stockholm, Sweden High-precision mass determination of unstable nuclei with a Penning trap mass spectrometer at ISOLDE/CERN, Switzerland High-precision mass measurements of rare isotopes using the LEBIT and SIPT Penning traps at the National Superconducting Cyclotron Laboratory, USA High-precision mass measurements of short-lived isotopes using the TITAN Penning trap at TRIUMF in Vancouver, Canada
Sources: en.wikipedia.org
== Drug treatments == Given the heterogeneity of mast cells and the complexity of the processes by which they release mediators, many compounds can affect mast cell behavior with both intended and unintended results. These include antihistamines, vitamins, glucocorticosteroids, monoclonal antibodies (mAbs), and flavonoids. Mast cell stabilizers block mast cell degranulation by stabilizing the cell membrane, preventing the release of mediators such as histamine. Mast cell stabilizers include sodium cromoglycate, ketotifen, pemirolast, nedocromil, and olopatadine. Glucocorticosteroids (GCs) reduce mast cell numbers, maturation and activation. Other approved therapies which directly target MCs include the following: Omalizumab (targets IgE); Imatinib, Midostaurin and Avapritinib (target KIT); and Cetirizine, Levocetirizine, Bilastine, Rupatadine, and Fexofenadine (target H1 histamine receptor). Anti-IgE mAbs such as Omalizumab block activation by themselves binding to the Cε3 domain of IgE. Omalizumab has been approved in the USA for treatment of allergic asthma, CSU, chronic rhinosinusitis with nasal polyps, and food allergies. Second generation H1 antihistamines, such as cetirizine, levocetirizine, bilastine, rupatadine and fexofenadine, neutralize histamine effector molecules by binding to the H1R receptor. Long-term regular administration of H1 antihistamines has been found to decrease symptoms in allergic rhinitis and CSU. A number of small molecule tyrosine kinase inhibitors (TKIs) have been approved for the treatment of mastocytosis.
Barbell Bowflex Bulgarian bag Cable machine Captains of Crush Grippers Dip bar Dumbbell Halteres (ancient Greece) Indian clubs Iron rings IronMind Kettlebell Leg press Power cage Shake Weight Smith machine Soloflex Swimming machine Total Gym Trap bar TRX System Universal Gym Equipment Utility bench Weight machine York Barbell
=== National Organizing Committee/League of Revolutionaries for a New America (1993) === In the January 1993 issue of Rally, Comrades! "An Open Letter” calling for a new organization was signed by Marian Kramer, President of the National Welfare Rights Union and General Baker, a UAW member and founder of the League of Revolutionary Black Workers. In the same issue of the paper a "Call to form Organizing Committees to establish an organization to educate, organize, and finally lead the masses in the inevitable transformation of our society” was published. It was signed by five activists: Abdul Alkalimat, Nacho Gonzalez, Ethel Long-Scott, John Slaughter and Leona Smith. Also in that issue was a statement by the CLP supporting the Call. The new organization was initially called the National Organizing Committee and later became the League of Revolutionaries for a New America.
== Description == An annual to perennial plant with creeping or erect branched stems to about 40 cm in height. The stems are square in cross-section and can vary from hairless on some plants to densely hairy on others, with a green to sometimes red or purplish colour. The leaves, which grow in opposite pairs, are narrowly oval, 2–3 cm long x 1 cm wide, downy, sparsely toothed towards the tip, and taper into a short stalk. All parts of the plant are strongly scented when crushed but it does not have noticeable glands on its surface. The small (6 mm) flowers are densely packed in whorls at the nodes, widely separated, above pairs of leaf-like bracts. The calyx is a ribbed tube about 3 mm long, with five triangular teeth, the lower two being narrower and slightly longer than the upper three; it is hairy both on the inside and the outside. The corolla has four mauve lobes or "petals" and is hairy only on the outside. The flowers are bisexual and have four long stamens, two (or all four) of which project well beyond the corolla lobes. There is one long style which is forked to produce two stigmas, which also project from the flower. The fruits consist of a cluster of four brown, 1-seeded nutlets, each about 0.7 mm long.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
Most listings describe it as a short acetylated peptide with the sequence Ac-LKKTETQ, presented as a region of thymosin beta-4. The label is a trade-style name rather than a standardized chemical name, so the exact content of a given vial depends on the supplier.